期刊文献+

国产那格列奈对2型糖尿病患者血糖和胰岛素分泌的影响

下载PDF
导出
摘要 目的:探讨国产那格列奈对2型糖尿病(T2DM)患者血糖和胰岛素的影响。方法:25例2型糖尿病患者口服国产那格列奈片120mg/次,3次/d,未用磺脲类降糖药。治疗前及治疗12周后测空腹血糖(FBG)、餐后1h血糖(1hPBG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、餐后1h胰岛素(1hINS)、餐后2h胰岛素(2hINS)。结果:治疗12周时,与用药前比较,1hPBG、2hBPG、HbA1c明显降低(P<0.01),餐后1hINS增加,与治疗前相比差异有统计学意义(P<0.05)。结论:国产那格列奈有明显降低餐后血糖和HbA1c作用,能促进1hINS的分泌。
出处 《广西医科大学学报》 CAS 2009年第2期278-279,共2页 Journal of Guangxi Medical University
  • 相关文献

参考文献8

  • 1Barnett AH,Anderson DM,Shelley S,et al.A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes[J].Diabetes Obes Metab,2004,6(2):104-113.
  • 2李肖玲,陆国红,蒋贤武.那格列奈及其类似物的研究进展[J].医药导报,2006,25(2):140-142. 被引量:7
  • 3Katz A,Nambi SS,Mather K,et al.Quantitative insulin sensitity check index:a simple,accurate method of assessing insulin sensitivity in humans[J].J Clin Endcrinol Metab,2000,85:2 402-2 410.
  • 4Lider TR.FDA approves nateglinide for treatment of type 2 diabetes[J].Am J Health Syst Pharm,2001,58(4):285-288.
  • 5McLeod JF.Clinical pharmacokinetics of nateglinide:a rapidly-absorbed,short-acting insulinotropic agent[J].Clin Pharmacokinet,2004,43(2):97-120.
  • 6Quast U,Stephan D,Bieger S,et al.The impact of ATP-sensitive K channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium[J].Diabetes,2004,53(S3):S156-164.
  • 7Hu S,Wang S,Fanelli B,et al.Pancreatic β-cells K-ATP channel actively and membrane-blinding studies with Nateglinide:A comparison with sulfonyljureas and repaglinide[J].J Pharmacol Exp Ther,2000,293(2):444-452.
  • 8Fonseca V,Kelley D,Cefalu W,et al.Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus[J].Metabolism,2004,53(10):1 331-1 335.

二级参考文献15

  • 1Hu S,Wang S,Fanelli F,et al. Pancreatic β-cell KATP channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide[ J]. J Pharmacol Exp Ther,2000,293(2) :444 -452.
  • 2Weaver M L, Orwig B A, Rodriguez L C, et al. Pharmacokinetics and metabolism of nateglinide in humans [ J ]. Drug Metab Dispos, 2001,29(4) :415 -421.
  • 3Anonymous. FDA approves nateglinide for treatment of type 2 diabetes[ J ]. Am J Health-Syst Pharm ,2001,58 (4) :285 - 288.
  • 4Devineni D,Walter Y H,Smith H T,et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients[ J]. J Clin Pharmacol,2003,43 (2) : 163 - 170.
  • 5Saloranta C,Hershon K, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia[J]. J Clin Endocrinol Metab ,2002 ,87 ( 9 ) :4171 -4176.
  • 6Abrahamian H, Francesconi M, Loiskandl A, et al, Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring [J]. Diabetes Technol Ther,2004,6(1) :31 -37.
  • 7Hanefeld M ,Bouter K P, Dickinson S, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia[ J ]. Diabetes Care,2000,23 (2) :202 - 207.
  • 8Keilson L, Mather S, Walter Y H, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus[J] . J Clin Endocrinol Metab, 2000,85 :1081 - 1086.
  • 9Horton E S, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with mefformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes [ J ]. Diabetes Care, 2000,23( 11 ) :1660 - 1665.
  • 10Marre M, Van G L, Usadel K H, et al, Nateglinide improves glyeaemic control when added to metformin monothcrapy: results of a randomized trial with type 2 diabetes patients [J]. Diabetes Obes Metab,2002,4 (3) : 177 - 186.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部